Treace to Report First Quarter 2023 Financial Results on May 8, 2023

Rhea-AI Summary

Treace Medical Concepts (TMCI) announced it will release Q1 2023 financial results on May 8, 2023, after trading ends. The company, which focuses on surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ Procedure, aims to advance standards of care for bunion treatment. Treace estimates around 1.1 million Americans are annual surgical candidates for bunions, affecting approximately 65 million people nationwide. Following the financial results announcement, a conference call will be held at 4:30 PM ET, allowing investors to engage with management. Live and archived webcasts will be accessible through the company’s investor relations website.

Positive

• Treace's Lapiplasty® procedure addresses all three planes of bunion deformities, enhancing treatment effectiveness.
• The Adductoplasty® Midfoot Correction System expands the company's offerings for bunion patients.

Negative

• None.

PONTE VEDRA, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Monday, May 8, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com

FAQ

When will Treace Medical Concepts release its Q1 2023 financial results?

Treace Medical Concepts will release its Q1 2023 financial results on May 8, 2023.

What time is the Treace Medical conference call scheduled?

The conference call is scheduled for May 8, 2023, at 4:30 PM ET.

How many Americans are estimated to be surgical candidates for bunions?

Treace estimates that approximately 1.1 million Americans are annual surgical candidates for bunions.

What is the focus of Treace Medical Concepts?

Treace Medical Concepts focuses on advancing surgical treatments for bunions and related midfoot deformities.